Literature DB >> 15758457

The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice.

M Bliziotes1, M Gunness, A Eshleman, K Wiren.   

Abstract

Neurotransmitter regulation of bone metabolism has been a subject of increasing interest and investigation. Dopamine (DA) has been reported to have effects on calcium and phosphorus metabolism. The dopamine transporter (DAT) is believed to control the temporal and spatial activity of released DA by rapid uptake of the neurotransmitter into presynaptic terminals. We have evaluated the histologic and biomechanical properties of the skeleton in mice homozygous for deletion of the DA transporter gene (DAT (-/-)) to help delineate the role of DA in bone biology. We have demonstrated that DAT (-/-) mice have reduced bone mass and strength. DAT (-/-) animals have shorter femur length and dry weight, and lower ash calcium content. Cancellous bone volume in the DAT (-/-) proximal tibial metaphysis is significantly decreased with reduced trabecular thickness. DAT (-/-) vertebrae have lower cancellous bone volume as a consequence of increased trabecular spacing and reduced trabecular number, and cortical thickness and bone area in the femoral diaphysis are reduced. The ultimate bending load (femoral strength) for the DAT (-/-) mice is 30% lower than the wild-type mice. Thus, deletion of the DAT gene results in deficiencies in skeletal structure and integrity. Since serotonin (5-HT) plays a role as a regulator of craniofacial morphogenesis, we explored the expression and function of 5-HT receptors and the 5-HT transporter (5-HTT) in bone. Primary cultures of rat osteoblasts (rOB) and a variety of clonal osteoblastic cell lines including ROS 17/2.8, UMR 106-H5 and Py1a show mRNA expression for the 5-HTT, and the 5-HT(1A), 5-HT(1D), 5-HT(2A) and 5-HT(2B) receptors by RT-PCR analysis and immunoblot. A relatively high density of nanomolar affinity 5-HTT binding sites is present in ROS 17/2.8 and UMR 106-H5 cells. The maximal [(3)H]5-HT uptake rate in ROS cells was 110 pmol/10 min/well, with a K(m) value of 1.13 microM. In normal differentiating rOB cultures, 5-HTT functional activity was observed initially at day 25, and activity increased by almost eight-fold at day 31. In mature rOB cultures, the estimated density of [(125)I]RTI-55 binding sites was 600 fmol/mg protein. PMA treatment caused a significant 40% reduction in the maximal uptake rate of [(3)H]5-HT, an effect prevented by pretreatment with staurosporine. 5-HT potentiates the PTH-induced increase in AP-1 activity in UMR 106-H5 cells. In 5-HTT (-/-) animals, cancellous bone volume (BV/TV) in the lumbar vertebrae is reduced, with a trend toward decreased trabecular thickness and trabecular number. These results demonstrate that osteoblastic cells express a functional serotonin system, with mechanisms for responding to and regulating uptake of 5-HT, and disruption of the 5-HTT gene may cause osteopenia.

Entities:  

Year:  2002        PMID: 15758457

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  23 in total

1.  Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Osteoporos Int       Date:  2006-03-07       Impact factor: 4.507

Review 2.  Drug-induced osteoporosis: beyond glucocorticoids.

Authors:  Karine Briot; Christian Roux
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

Review 3.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

4.  Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study.

Authors:  Inbar Zucker; Gabriel Chodick; Leon Grunhaus; Ra'anan Raz; Varda Shalev
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

5.  Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study.

Authors:  C-Y Wang; S-H Fu; C-L Wang; P-J Chen; F-L L Wu; F-Y Hsiao
Journal:  Osteoporos Int       Date:  2015-07-01       Impact factor: 4.507

6.  The effect of psychostimulants on skeletal health in boys co-treated with risperidone.

Authors:  Chadi A Calarge; Janet A Schlechte; Trudy L Burns; Babette S Zemel
Journal:  J Pediatr       Date:  2015-04-08       Impact factor: 4.406

Review 7.  Depression and osteoporosis: epidemiology and potential mediating pathways.

Authors:  B Mezuk; W W Eaton; S H Golden
Journal:  Osteoporos Int       Date:  2007-09-01       Impact factor: 4.507

8.  Use of anti-depressants and the risk of fracture of the hip or femur.

Authors:  M W M van den Brand; S Pouwels; M M Samson; T P van Staa; B Thio; C Cooper; H G M Leufkens; A C G Egberts; H J J Verhaar; F de Vries
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

Review 9.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

10.  Osteocyte-Driven Downregulation of Snail Restrains Effects of Drd2 Inhibitors on Mammary Tumor Cells.

Authors:  Shengzhi Liu; Yao Fan; Andy Chen; Aydin Jalali; Kazumasa Minami; Kazuhiko Ogawa; Harikrishna Nakshatri; Bai-Yan Li; Hiroki Yokota
Journal:  Cancer Res       Date:  2018-05-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.